8 Stocks Jeff Bezos is Buying

5. Denali Therapeutics Inc. (NASDAQ:DNLI)

Number of Hedge Fund Holders: 30

Denali Therapeutics Inc. (NASDAQ:DNLI) is a biopharmaceutical company focused on developing treatments for neurodegenerative and lysosomal storage diseases, with a portfolio of candidates designed to cross the blood-brain barrier (BBB).

BofA Securities recently raised its price target for Denali Therapeutics Inc. (NASDAQ:DNLI) from $25 to $29, while maintaining a Buy rating. This upgrade follows Denali’s progress with the FDA on its therapy for Hunter syndrome, tividenofusp alfa (tivi; DNL310). The company has reached an agreement with the FDA for an accelerated approval pathway, using cerebrospinal heparan sulfate (CSF HS) as a surrogate biomarker. Denali Therapeutics Inc. (NASDAQ:DNLI) also plans to file a Biologics License Application (BLA) in early 2025, anticipating a priority review.

As of Q2 2024, 30 hedge funds held positions in Denali Therapeutics Inc. (NASDAQ:DNLI), with a total value of $390 million. The largest shareholder among them is Baker Bros. Advisors, owning 2.3 million shares worth $47 million.